Cash Flow Statement (Annual)
GHDX / Genomic Health, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
Peers - Medical Laboratories (8071)
BIOC / Biocept, Inc.
CDNA / CareDx, Inc.
CGIX / Cancer Genetics, Inc.
FMI / Foundation Medicine, Inc.
Related News Stories
GNC Holdings, Inc. (GNC - Free Report) has been gaining investor confidence on stellar results over an extended period. Year to date, the company’s stock has outperformed its industry. The stock has gained 11.2% against the industry’s 2.2% rise. (0-2)
Amedisys, Inc. (AMED - Free Report) recently inked an agreement to buy national hospice care provider —Compassionate Care Hospice. Amedisys is slated to pay $340 million, which includes $50 million in payments related to a tax asset and working capital for acquiring 100% ownership interest in Compassionate Care Hospice. The transaction is expected to close by Feb 1, 2019. (1-0)
Myriad Genetics recently signed a commercialization plan with Pfizer Inc. (PFE - Free Report) for FDA approval to use its BRACAnalysis CDx as a companion diagnostic with the latter’s talazoparib. Meanwhile, Thermo Fisher Scientific Inc. (TMO - Free Report) announced the sixth licensing agreement for its B·R·A·H·M·S PCT (procalcitonin) biomarker. In fact, there are many similar developments that clearly point toward the rapid emergence of molecular diagnostics in the MedTech space. (4-0)
Genomic Health, Inc. (GHDX - Free Report) has been gaining investor confidence on stellar results over an extended period. Over the past year, the company’s share price has outperformed its industry. The stock has gained 103.2% against the industry’s 18.6% fall. Also, the company has fared better than the S&P 500’s 13.9% rise. (1-0)
Genomic Health, Inc. (GHDX - Free Report) recently announced the publication of real-world clinical data supporting the use of the Oncotype DX Genomic Prostate Score (GPS) test, which has resulted in substantially greater use of active surveillance compared to no testing. Results of this new study were published in Reviews in Urology. (3-1)
as of ET